Achillion Pharmaceuticals (NASDAQ:ACHN) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02, MarketWatch Earnings reports.
ACHN traded down $0.07 during trading on Thursday, hitting $2.99. The company’s stock had a trading volume of 812,700 shares, compared to its average volume of 1,479,922. Achillion Pharmaceuticals has a twelve month low of $2.33 and a twelve month high of $4.34. The firm has a market cap of $408.83 million, a P/E ratio of -4.82 and a beta of 1.69.
Separately, BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $4.38.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
See Also: Discover Your Risk Tolerance
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.